» Articles » PMID: 30761374

MRI Texture Analysis for Differentiation of Malignant and Benign Hepatocellular Tumors in the Non-cirrhotic Liver

Overview
Journal Heliyon
Specialty Social Sciences
Date 2019 Feb 15
PMID 30761374
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To find potentially diagnostic texture analysis (TA) features and to evaluate the diagnostic accuracy of two-dimensional (2D) magnetic resonance (MR) TA for differentiation between hepatocellular carcinoma (HCC) and benign hepatocellular tumors in the non-cirrhotic liver in an exploratory MR-study.

Materials And Methods: 108 non-cirrhotic patients (62 female; 41.5 ± 18.3 years) undergoing preoperative contrast-enhanced MRI were retrospectively included in this multi-center-study. TA including gray-level histogram, co-occurrence and run-length matrix features (total 19 features) was performed by two independent readers. Native fat-saturated-T1w and T2w as well as arterial and portal-venous post contrast-enhanced 2D-image-slices were assessed. Conventional reading was performed by two separate independent readers. Differences in TA features between HCC and benign lesions were investigated using independent sample t-tests. Logistic regression analysis was performed to obtain the optimal number/combination of TA-features and diagnostic accuracy of TA analysis. Sensitivity and specificity of the better performing radiologist were compared to TA analysis.

Results: The highest number of significantly differing TA-features (n = 5) was found using the arterial-phase images including one gray-level histogram (skewness, p = 0.018) and four run-length matrix features (all, p < 0.02). The optimal binary logistic regression model for TA-features of the arterial-phase images contained 13 parameters with an accuracy of 84.5% (sensitivity 84.1%, specificity 84.9%) and area-under-the-curve of 0.92 (95%-confidence-interval 0.85-0.98) for diagnosis of HCC. Conventional reading yielded a significantly lower sensitivity (63.6%, p = 0.027) and no significant difference in specificity (94.6%, p = 0.289) at best.

Conclusion: 2D-TA of MR images is a feasible objective method that may help to distinguish HCC from benign hepatocellular tumors in the non-cirrhotic liver. Most promising results were found in TA features in the arterial phase images.

Citing Articles

Texture analysis on routine MRI sequences to differentiate between focal nodular hyperplasia and hepatocellular adenoma.

Salahshour F, Ghamari Khameneh A, Darban Hosseini Amirkhiz G, Ayoobi Yazdi N, Shafiekhani S Pol J Radiol. 2024; 88:e589-e596.

PMID: 38362015 PMC: 10867978. DOI: 10.5114/pjr.2023.134043.


Current status of magnetic resonance imaging radiomics in hepatocellular carcinoma: A quantitative review with Radiomics Quality Score.

Brancato V, Cerrone M, Garbino N, Salvatore M, Cavaliere C World J Gastroenterol. 2024; 30(4):381-417.

PMID: 38313230 PMC: 10835534. DOI: 10.3748/wjg.v30.i4.381.


Comparing Texture Analysis of Apparent Diffusion Coefficient MRI in Hepatocellular Adenoma and Hepatocellular Carcinoma.

Abdullah A, Amanpour-Gharaei B, Toosi M, Delazar S, Saligheh Rad H, Arian A Cureus. 2024; 16(1):e51443.

PMID: 38298321 PMC: 10829059. DOI: 10.7759/cureus.51443.


Focal Lesions of the Liver and Radiomics: What Do We Know?.

Anichini M, Galluzzo A, Danti G, Grazzini G, Pradella S, Treballi F Diagnostics (Basel). 2023; 13(15).

PMID: 37568954 PMC: 10417608. DOI: 10.3390/diagnostics13152591.


Diagnostic Values of the Liver Imaging Reporting and Data System in the Detection and Characterization of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Arian A, Abdullah A, Taher H, Suhail Alareer H, Fotouhi M Cureus. 2023; 15(3):e36082.

PMID: 37065286 PMC: 10097431. DOI: 10.7759/cureus.36082.


References
1.
Burrel M, Llovet J, Ayuso C, Iglesias C, Sala M, Miquel R . MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003; 38(4):1034-42. DOI: 10.1053/jhep.2003.50409. View

2.
Llovet J, Burroughs A, Bruix J . Hepatocellular carcinoma. Lancet. 2003; 362(9399):1907-17. DOI: 10.1016/S0140-6736(03)14964-1. View

3.
Llovet J, Fuster J, Bruix J . The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004; 10(2 Suppl 1):S115-20. DOI: 10.1002/lt.20034. View

4.
Sherman M . Pathogenesis and screening for hepatocellular carcinoma. Clin Liver Dis. 2004; 8(2):419-43, viii. DOI: 10.1016/j.cld.2004.02.002. View

5.
Yu M, Yuan J . Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004; 127(5 Suppl 1):S72-8. DOI: 10.1016/j.gastro.2004.09.018. View